Impaired maturation of cortical GABA(A) receptor expression in pediatric epilepsy

Laura A Jansen1, Lindsey D Peugh, William H Roden

  • 1Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. laura.jansen@seattlechildrens.org

Epilepsia
|February 6, 2010
PubMed

Insights

Brain GABA(A) receptor subunit expression matures postnatally in humans. This developmental pattern is disrupted in children with intractable focal epilepsy, impacting treatment strategies for these conditions.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Molecular Biology

Background:

  • GABA(A) receptor subunit expression changes during postnatal brain development in animal models.
  • Understanding these changes in humans is crucial for neurological development and disease.

Purpose of the Study:

  • To analyze cortical GABA(A) receptor subunit expression in human infants through adolescence.
  • To compare expression patterns in control subjects with those in children suffering from intractable focal epilepsy.

Main Methods:

  • Quantitative western blot analysis of neocortical specimens from pediatric controls and epileptic children.
  • Correlation of subunit expression with clinical factors like age, pathology, and medication.

Main Results:

  • In controls, GABA(A) receptor subunits (α₁ and γ₂) increased with age, while α₄ decreased. Chloride transporters KCC2 and NKCC1 showed age-dependent changes.
  • These typical developmental patterns were absent in children with epilepsy.
  • Epileptic children displayed variable but individual-specific GABA(A) receptor subunit expression patterns.

Conclusions:

  • Cortical GABA(A) receptor subunit expression undergoes significant maturation during early postnatal human development.
  • Intractable focal epilepsy in children disrupts this normal developmental trajectory.
  • Findings suggest implications for therapeutic interventions targeting GABA(A) receptors in pediatric epilepsy.
Abstract

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...